CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
If you're new to automated investing, this primer covers concepts, benefits, and first steps to start investing with automation.
10,865 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
When Alphabet joins the Dow Jones Industrial Average, it signals a shift in how blue-chip names are chosen and weight...
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Public chatter suggests a behind-the-camera path for a young star. This article breaks down the personal-finance impl...
OpenAI accelerates its shift from software to silicon and bio bets, unveiling a custom chip, a DRAM stake, and a majo...
As lithium demand climbs, Albemarle sits at a crossroads. This article breaks down the lithium rise again. does dynam...
Two AI-era stock stories headline this guide: Palantir as an undervalued growth play and Sandisk as a growth leader w...
Savers are exploring dividend income to take home an electrician’s paycheck, but the capital required hinges on yield...
Medicare will cover GLP-1 weight-loss drugs for eligible beneficiaries beginning this week, a policy shift that could...
A single, six-word moment reshaped how Wall Street reads the Fed. This article explores what happened, why it matters...
Two software leaders battle for your 2026 portfolio: Duolingo and Zeta Global. This guide compares business models, g...
May data show 7.6 million job openings, topping forecasts and signaling stabilization in the labor market. Thursday's...